Pharmasset Inc. has discontinued use of an experimental hepatitis C drug in a clinical trial because of safety concerns, but the drug maker said the setback wouldn't derail its planned sale to Gilead Sciences Inc. for nearly $11 billion.
The company said Friday it discontinued use of a drug code-named PSI-938 in a midstage study of people with hepatitis C infection, citing "laboratory abnormalities associated with liver function." However, it will continue testing its lead hepatitis C drug candidate, PSI-7977, which was the primary selling point behind the Gilead deal and ...
Read more....
1 comments:
This is a risk associated with clinical trials. However, in this case, the people that were taking the drugs are likely below the limit of detection and will now relapse. I wonder what Pharmasset is doing for these people. I found it very odd that they didn't roll the people over into the 7977 arms of the study.
Post a Comment